The DOI matches its Crossref record; 41 of the 41 references it cites were found in a registry or an index.
Clinical and Biological Effects of Mifepristone Treatment for Psychotic Depression
Abstract
Psychotic major depression (PMD) is found to be a relatively common psychiatric condition that affects up to nearly 20% of patients with major depression. Previous studies by our group have shown rapid reversal of psychotic symptoms in some PMD patients treated with mifepristone, in addition to restoring a more normal afternoon cortisol release. The rationale for treating patients with PMD with a glucocorticosteroid receptor antagonist is further discussed. In total, 30 patients with PMD were treated with either 600 mg/day mifepristone or placebo for 8 days in a randomized double-blind manner. The Hamilton Depression Rating Scale (HDRS) and the Brief Psychiatric Rating Scale (BPRS) were administered at baseline and again after 8 days of treatment. Cortisol and ACTH were measured hourly from 1800 to 0900 at baseline and after 8 days of treatment. Significantly, more patients in the mifepristone group (seven of 15) showed a 50% or greater decline on the BPRS positive symptom subscale, an index of psychotic symptoms, as compared to the placebo group (two of 15). Patients who received mifepristone had lower HDRS and BPRS scores at study completion compared to those who received placebo, but these differences were not statistically significant. In addition, mifepristone significantly elevated cortisol and ACTH levels and steepened ascending slopes from 1800 to 0100 and from 0100 to 0900 as compared to placebo. Clinical and biological effects of mifepristone were comparable among males and females. Age was found to significantly and positively correlate with changes in cortisol and ACTH. These results suggest that short-term use of mifepristone may be effective in the treatment of PMD and may re-regulate the HPA axis. Additional blinded studies are warranted.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“4 double-blind [89-92] and 2 open-label trials [93, 94] suggested a significant reduction in psychotic symptoms, which was the primary outcome of these trials.”
From The HPA Axis as Target for Depression (2024) · cites this paper as [91]
In the citing paper
“Of note, depressive symptoms were considered secondary outcomes, and these trials often failed to show a significant improvement compared to placebo.”
From The HPA Axis as Target for Depression (2024) · cites this paper as [91]
Citations
Cites
Hamilton, M. (1960) · Journal of Neurology, Neurosurgery & Psychiatry · doi:10.1136/jnnp.23.1.56 · Cited by 32,817 · cited 3×
“…procedures included the Structured Clinical Interview for the DSM-IV (SCID; First et al, 1997), the 21-item Hamilton Depression Rating Scale (HDRS; Hamilton, 1980), the Brief Psychiatric Rating Scale (BPRS; Overall and Gorham, 1961), and clinical laboratory tests (complete blood count,…”
MethodThe Brief Psychiatric Rating Scale.
Overall, J. E., & Gorham, D. R. (1962) · Psychological Reports · doi:10.2466/pr0.1962.10.3.799 · Cited by 11,090 · cited 3×
“The Hamilton Depression Rating Scale (HDRS) and the Brief Psychiatric Rating Scale (BPRS) were administered at baseline and again after 8 days of treatment.”
MethodBrain corticosteroid receptor balance and homeostatic control
de Kloet, E. R. (1991) · Frontiers in Neuroendocrinology · Cited by 842
Disrupted 24-hour patterns of cortisol secretion in psychotic depression
Sachar, E. J. (1973) · Archives of General Psychiatry · doi:10.1001/archpsyc.1973.01750310011002 · Cited by 775 · cited 1×
“…they demonstrate excessive hypothalamic–pituitary–adrenal (HPA) axis activity, as evidenced by elevated urinary free cortisol levels (Kathol et al, 1989), elevated evening and night time cortisol levels (Sachar et al, 1973), and high rates of dexamethasone nonsuppression (Nelson and Davis, 1997).”
BackgroundLupien, S. J., Gillin, C. J., & Hauger, R. L. (1999) · Behavioral Neuroscience · doi:10.1037/0735-7044.113.3.420 · Cited by 561 · cited 1×
“Administration of glucocorticoids to healthy controls (Lupien et al, 1999; Newcomer et al, 1999) results in cognitive deficits similar to those seen with PMD (Schatzberg et al, 2000; Fleming et al, 2004; Hill et al, 2004).”
ResultDecreased memory performance in healthy humans induced by stress-level cortisol treatment
Newcomer, J. W. (1999) · Archives of General Psychiatry · doi:10.1001/archpsyc.56.6.527 · Cited by 546 · cited 1×
“Administration of glucocorticoids to healthy controls (Lupien et al, 1999; Newcomer et al, 1999) results in cognitive deficits similar to those seen with PMD (Schatzberg et al, 2000; Fleming et al, 2004; Hill et al, 2004).”
ResultFunctional biology of intestinal goblet cells
Specian, R. D., & Oliver, M. G. (1991) · American Journal of Physiology-Cell Physiology · doi:10.1152/ajpcell.1991.260.2.c183 · Cited by 467
The pharmacological treatment of delusional depression
(1985) · American Journal of Psychiatry · doi:10.1176/ajp.142.4.430 · Cited by 357
DST Studies in Psychotic Depression: A Meta-Analysis
Nelson, J. C., & Davis, J. M. (1997) · American Journal of Psychiatry · doi:10.1176/ajp.154.11.1497 · Cited by 356 · cited 2×
“Most notably, they demonstrate excessive hypothalamic–pituitary–adrenal (HPA) axis activity, as evidenced by elevated urinary free cortisol levels (Kathol et al, 1989), elevated evening and night time cortisol levels (Sachar et al, 1973), and high rates of dexamethasone nonsuppression (Nelson and Davis, 1997).”
BackgroundAn open label trial of C-1073 (mifepristone) for psychotic major depression*
Belanoff, J. K., Rothschild, A. J., Cassidy, F., DeBattista, C., Baulieu, E.-E., Schold, C., & Schatzberg, A. F. (2002) · Biological Psychiatry · doi:10.1016/s0006-3223(02)01432-4 · Cited by 320
Self-citation
Research works printed but not linked: 1
- First MB, Spitzer RL, Gibbon M, Williams JBW (1997). Structured Clinical Interview for DSM IV-TR Axis I Disorders—Patient Edition (SCID-I/P, 2/2001 revision). American Psychiatric Press, Inc.: Washington, DC.
Cited by
Molecular Mechanisms of Depression: Perspectives on New Treatment Strategies
Lang, U. E., & Borgwardt, S. (2013) · Cellular Physiology and Biochemistry · doi:10.1159/000350094 · Cited by 8,475
Belmaker, R. H., & Agam, G. (2008) · New England Journal of Medicine · doi:10.1056/nejmra073096 · Cited by 2,166
The HPA axis in major depression: classical theories and new developments
Pariante, C. M., & Lightman, S. L. (2008) · Trends in Neurosciences · doi:10.1016/j.tins.2008.06.006 · Cited by 2,009
New approaches to antidepressant drug discovery: beyond monoamines
Berton, O., & Nestler, E. J. (2006) · Nature Reviews Neuroscience · doi:10.1038/nrn1846 · Cited by 1,589
Anderson, I., Ferrier, I., Baldwin, R., Cowen, P., Howard, L., Lewis, G., Matthews, K., McAllister-Williams, R., Peveler, R., Scott, J., et al. (2008) · Journal of Psychopharmacology · doi:10.1177/0269881107088441 · Cited by 908
Metadata
- Authors
- Flores, B. H., Kenna, H., Keller, J., Solvason, H. B., & Schatzberg, A. F.
- Affiliations
- Stanford University (US)
- Stanford Medicine (US)
- Corresponding author
- Flores, Benjamin H
- Venue
- Neuropsychopharmacology
- Published
- 2005-09-14
- Volume
- 31
- Issue
- 3
- Pages
- 628-636
- ISSN
- 0893-133X (ISSN-L)
- 1740-634X
- OpenAlex
- W2081535802
- Cited by
- 203
- References
- 41
- Citations by year
- 2026: 1 · 2025: 4 · 2024: 4 · 2023: 7 · 2022: 4 · 2021: 5 · 2020: 3 · 2019: 4 · 2018: 12 · 2017: 9 · 2016: 9 · 2015: 10 · 2014: 12 · 2013: 13 · 2012: 11
- FWCI
- 11.70
- Type
- journal article
- Language
- en
- Open access
- closed
- Licence
- www.springer.com/tdm (tdm)
- Locations
- Neuropsychopharmacology (publishedVersion)
- PubMed (publishedVersion)
- Funders
- National Institutes of Health (MH50604)
- National Institute of Mental Health (R0-1MH50604, MH-47573, R01MH050604, R01 MH 47573, R01MH047573, T32MH019938)
- National Center for Research Resources (M01RR000070)
- Topics
- Health Sciences › Medicine › Pharmacology (medical) › Treatment of Major Depression
- Life Sciences › Neuroscience › Behavioral Neuroscience › Stress Responses and Cortisol
- Health Sciences › Medicine › Psychiatry and Mental health › Schizophrenia research and treatment
- Keywords
- mifepristone, psychotic depression, glucocorticoid receptor antagonist, hypothalamic-pituitary-adrenal axis, cortisol, ACTH, depression treatment
- MeSH terms
- Adrenocorticotropic Hormone, Adult, Major Depressive Disorder, Depressive Disorder, Major, Double-Blind Method, Female, Hormone Antagonists, Humans, Hydrocortisone, Hypothalamo-Hypophyseal System, Male, Psychiatric Status Rating Scales, Receptors, Glucocorticoid, Sex Characteristics, Mifepristone, Linear Models
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Clinical and Biological Effects of Mifepristone Treatment for Psychotic Depression. https://app.cochat.ai/papers/10.1038/sj.npp.1300884
- The paper
- Flores, B. H., Kenna, H., Keller, J., Solvason, H. B., & Schatzberg, A. F. (2006). Clinical and Biological Effects of Mifepristone Treatment for Psychotic Depression. Neuropsychopharmacology. https://doi.org/10.1038/sj.npp.1300884
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.